Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
This study is an open label phase I/II trial to investigate the safety and efficacy of Cabozantinib for patients with relapsed or refractory myeloma.
Relapsed or Refractory Multiple Myeloma
DRUG: Cabozantinib (XL184)
Maximally Tolerated Dose, This trial will be a standard 3 by 3 dose escalation design, where three daily dose levels (20mg, 40mg, and 60mg) will be investigated., 1 year
Overall Response Rate, IMWG Criteria for Response, Progression and Relapse in Multiple Myeloma Patients, 1 year|Safety and Toxicity in This Patient Population, Safety assessments and toxicity grading will follow CTCAE Version 4 Grade, 1 year|Time to Progression (TTP), 1 year|Duration of Response (DOR), 1 year
This study is an open label phase I/II trial to investigate the safety and efficacy of Cabozantinib for patients with relapsed or refractory myeloma.